Patients enrolled in a phase III trial of a novel Bcl-2-directed antisense agent plus chemotherapy with dacarbazine (DTIC) are yielding remarkable responses thus far, according to Anna C. Pavlick, D.O., assistant professor of medicine, New York University School of Medicine, New York.